Genomic Profiling for Lung Cancer: Improving Access to this Important Tool

Abstract

Get full access to this article

View all access options for this article.

References

NCCN Guidelines Lung Cancer. www.nccn.org/guidelines/guidelines-detail?category=1&id=1450

Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer. www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=54795&ver=39

Schwartzberg

, Li

, Tolba

, et al. Complementary Roles for Tissue-and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC. JTO Clin Res Rep , 2022; 3:100386.

Hughes

, Kapiris

, Podvez Nevajda

, et al. Non-small cell lung cancer (NSCLC) in young adults, age < 50, is associated with late stage at presentation and a very poor prognosis in patients that do not have a targeted therapy option: A real-world study. Cancers , 2022; 16: 6056.

Early Diagnosis Data Hub, Cancer Research UK. crukcancerintelligence.shinyapps.io/EarlyDiagnosis/